JP2010504280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504280A5 JP2010504280A5 JP2009520761A JP2009520761A JP2010504280A5 JP 2010504280 A5 JP2010504280 A5 JP 2010504280A5 JP 2009520761 A JP2009520761 A JP 2009520761A JP 2009520761 A JP2009520761 A JP 2009520761A JP 2010504280 A5 JP2010504280 A5 JP 2010504280A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- chloro
- triazol
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 T-Butyl Chemical group 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004429 atom Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 3
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 3
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- XQQNPZZMXRJVDN-UHFFFAOYSA-N 3,4-dichloro-n-[5-chloro-2-[4-(1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]pyridin-3-yl]benzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=CN1C=1C=CNN=1 XQQNPZZMXRJVDN-UHFFFAOYSA-N 0.000 claims 1
- FZFLWOHYWMSSFG-UHFFFAOYSA-N 4-chloro-n-[5-chloro-2-[4-(4-methyl-1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CNN=C1N1C(C=2C(=CC(Cl)=CN=2)NS(=O)(=O)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=NN=C1 FZFLWOHYWMSSFG-UHFFFAOYSA-N 0.000 claims 1
- JELORYBSSKXTKS-UHFFFAOYSA-N 5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-n,n-dimethyl-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)N(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 JELORYBSSKXTKS-UHFFFAOYSA-N 0.000 claims 1
- HMCRGZKZGJIKHJ-UHFFFAOYSA-N 5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-n-methyl-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 HMCRGZKZGJIKHJ-UHFFFAOYSA-N 0.000 claims 1
- KPBBXPDMTLDHTE-UHFFFAOYSA-N 5-[3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]-5-methylpyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1S(=O)(=O)NC1=CC(C)=CN=C1C1=NN=C(C(N)=O)N1C=1C=CON=1 KPBBXPDMTLDHTE-UHFFFAOYSA-N 0.000 claims 1
- QHAFGHWVHRRHSV-UHFFFAOYSA-N 5-[3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]-5-methylpyridin-2-yl]-4-phenyl-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1S(=O)(=O)NC1=CC(C)=CN=C1C1=NN=C(C(N)=O)N1C1=CC=CC=C1 QHAFGHWVHRRHSV-UHFFFAOYSA-N 0.000 claims 1
- NUOLRQJDNCPPQU-UHFFFAOYSA-N 5-[5-chloro-3-[(3,4-dichlorophenyl)sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 NUOLRQJDNCPPQU-UHFFFAOYSA-N 0.000 claims 1
- CWEXICJJEOCLLQ-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 CWEXICJJEOCLLQ-UHFFFAOYSA-N 0.000 claims 1
- SAIRUSJXGAIIKQ-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-n-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)NC(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 SAIRUSJXGAIIKQ-UHFFFAOYSA-N 0.000 claims 1
- QDTKHLLJQIJDAD-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(N)=O)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 QDTKHLLJQIJDAD-UHFFFAOYSA-N 0.000 claims 1
- MYDSZQFQVRXQPG-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n,n-dimethyl-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 MYDSZQFQVRXQPG-UHFFFAOYSA-N 0.000 claims 1
- BTFFJIJPEWHEEM-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n,n-dimethyl-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)N(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 BTFFJIJPEWHEEM-UHFFFAOYSA-N 0.000 claims 1
- DDTYMWFASCHUPO-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n-ethyl-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)NCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 DDTYMWFASCHUPO-UHFFFAOYSA-N 0.000 claims 1
- GUNCDSYWZPBVIR-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n-ethyl-n-methyl-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N(C)CC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 GUNCDSYWZPBVIR-UHFFFAOYSA-N 0.000 claims 1
- ZOPRRQNFZVBNDG-UHFFFAOYSA-N 5-[5-chloro-3-[[4-methyl-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=C(C(N)=O)N1C1=NOC=C1 ZOPRRQNFZVBNDG-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- PYJQQZKGTZDDHZ-UHFFFAOYSA-N C1(=CC=CC=C1)S(=O)(=O)NC=1C(=NC=C(C=1)C)C1=NN=CN1C1CNCC1 Chemical compound C1(=CC=CC=C1)S(=O)(=O)NC=1C(=NC=C(C=1)C)C1=NN=CN1C1CNCC1 PYJQQZKGTZDDHZ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010063725 Idiopathic pneumonia syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- BKAKNTTWTRQBBK-UHFFFAOYSA-N O=C(C1=NN=C(C(C=C2)=NC=C2Cl)N1C1=NOC=C1)N1CCOCC1 Chemical compound O=C(C1=NN=C(C(C=C2)=NC=C2Cl)N1C1=NOC=C1)N1CCOCC1 BKAKNTTWTRQBBK-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000001760 anti-analgesic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VXHXALJHPTYTDH-UHFFFAOYSA-N ethyl 5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-4-propan-2-yl-1,2,4-triazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 VXHXALJHPTYTDH-UHFFFAOYSA-N 0.000 claims 1
- LWNVJYPBMIIDOF-UHFFFAOYSA-N ethyl 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxylate Chemical compound C1=CON=C1N1C(C(=O)OCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LWNVJYPBMIIDOF-UHFFFAOYSA-N 0.000 claims 1
- PWQMLLBKSFCCRB-UHFFFAOYSA-N ethyl 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-propan-2-yl-1,2,4-triazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 PWQMLLBKSFCCRB-UHFFFAOYSA-N 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000007915 ichthyosis prematurity syndrome Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- JTDBSXSLPVDHRS-UHFFFAOYSA-N n-[2-(5-amino-4-propan-2-yl-1,2,4-triazol-3-yl)-5-chloropyridin-3-yl]-4-chloro-3-(trifluoromethyl)benzenesulfonamide Chemical compound CC(C)N1C(N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 JTDBSXSLPVDHRS-UHFFFAOYSA-N 0.000 claims 1
- BLTWVOMRRFJFON-UHFFFAOYSA-N n-[2-(5-amino-4-propan-2-yl-1,2,4-triazol-3-yl)-5-chloropyridin-3-yl]-4-tert-butylbenzenesulfonamide Chemical compound CC(C)N1C(N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 BLTWVOMRRFJFON-UHFFFAOYSA-N 0.000 claims 1
- ZHABSIKVUSRSKW-UHFFFAOYSA-N n-[2-[4-(4-bromo-1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=CN1C1=NNC=C1Br ZHABSIKVUSRSKW-UHFFFAOYSA-N 0.000 claims 1
- IUCAQAZBATXHQF-UHFFFAOYSA-N n-[2-[5-bromo-4-(1,2-oxazol-3-yl)-1,2,4-triazol-3-yl]-5-chloropyridin-3-yl]-4-chloro-3-(trifluoromethyl)benzenesulfonamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)NC=2C(=NC=C(Cl)C=2)C=2N(C(Br)=NN=2)C2=NOC=C2)=C1 IUCAQAZBATXHQF-UHFFFAOYSA-N 0.000 claims 1
- WLIXWPBIQOBJGW-UHFFFAOYSA-N n-[2-[5-bromo-4-(4-bromo-1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=C(Br)N1C1=NNC=C1Br WLIXWPBIQOBJGW-UHFFFAOYSA-N 0.000 claims 1
- MCUNGNKSMZSFRI-UHFFFAOYSA-N n-[5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-4-propan-2-yl-1,2,4-triazol-3-yl]acetamide Chemical compound CC(C)N1C(NC(C)=O)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 MCUNGNKSMZSFRI-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83104206P | 2006-07-14 | 2006-07-14 | |
| US60/831,042 | 2006-07-14 | ||
| US94585407P | 2007-06-22 | 2007-06-22 | |
| US60/945,854 | 2007-06-22 | ||
| PCT/US2007/015786 WO2008008375A2 (en) | 2006-07-14 | 2007-07-10 | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010504280A JP2010504280A (ja) | 2010-02-12 |
| JP2010504280A5 true JP2010504280A5 (enExample) | 2012-02-16 |
| JP5320291B2 JP5320291B2 (ja) | 2013-10-23 |
Family
ID=38670575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520761A Active JP5320291B2 (ja) | 2006-07-14 | 2007-07-10 | トリアゾリルピリジルベンゼンスルホンアミド類 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7683176B2 (enExample) |
| EP (1) | EP2049515B1 (enExample) |
| JP (1) | JP5320291B2 (enExample) |
| CN (1) | CN101511800B (enExample) |
| AT (1) | ATE496905T1 (enExample) |
| AU (1) | AU2007272972B2 (enExample) |
| CA (1) | CA2657670C (enExample) |
| DE (1) | DE602007012261D1 (enExample) |
| ES (2) | ES2358618T3 (enExample) |
| WO (1) | WO2008008375A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| WO2009126675A1 (en) * | 2008-04-09 | 2009-10-15 | Boehringer Ingelheim International Gmbh | 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| EP2598481B1 (en) | 2010-07-26 | 2016-08-31 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as cyp17 inhibitors |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| US20140329809A1 (en) | 2011-10-28 | 2014-11-06 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| PT2953942T (pt) | 2013-02-06 | 2018-01-17 | Bayer Cropscience Ag | Derivados de pirazol substituídos com halogéneo como agentes pesticidas |
| JP6417415B2 (ja) | 2013-07-29 | 2018-11-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | １，３−二置換シクロペンタン誘導体 |
| ES2735360T3 (es) * | 2013-12-02 | 2019-12-18 | Chemocentryx Inc | Compuestos CCR6 |
| EP3087069B1 (en) | 2013-12-23 | 2019-01-30 | Norgine B.V. | Compounds useful as ccr9 modulators |
| EP3087074A1 (en) | 2013-12-23 | 2016-11-02 | Norgine BV | Benzene sulfonamides as ccr9 inhibitors |
| JP6556825B2 (ja) * | 2014-03-21 | 2019-08-07 | トビラ セラピューティクス， インコーポレイテッド | 線維症を処置するためのセニクリビロック |
| ES2971041T3 (es) | 2014-10-06 | 2024-06-03 | Chemocentryx Inc | Terapia combinada de inhibidores del receptor 9 de quimiocina C-C (CCR9) y anticuerpos bloqueadores anti-integrina alfa4beta7 para el tratamiento de la enfermedad inflamatoria intestinal |
| CN104341389A (zh) * | 2014-10-19 | 2015-02-11 | 湖南华腾制药有限公司 | 一种三唑哌啶盐酸盐的制备方法 |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| US10000458B2 (en) * | 2016-03-31 | 2018-06-19 | Sumitomo Chemical Company, Limited | Production method of 1, 2, 4-triazole compound |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| RU2740902C2 (ru) * | 2016-06-03 | 2021-01-21 | Хемоцентрикс, Инк. | Способ лечения фиброза печени |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| TW201833108A (zh) | 2017-03-03 | 2018-09-16 | 大陸商江蘇豪森藥業集團有限公司 | 醯胺類衍生物抑制劑及其製備方法和應用 |
| GB201705263D0 (en) | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| EP3655402A1 (de) | 2017-07-18 | 2020-05-27 | Bayer CropScience Aktiengesellschaft | Substituierte 3-heteroaryloxy-1h-pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス， インコーポレイテッド | Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
| AU2019383976B2 (en) | 2018-11-19 | 2025-07-03 | Bt Bidco, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP3996711A4 (en) | 2019-07-10 | 2023-08-16 | ChemoCentryx, Inc. | Indanes as pd-l1 inhibitors |
| US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| KR20220084119A (ko) | 2019-10-16 | 2022-06-21 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드 |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN115484944A (zh) | 2020-03-31 | 2022-12-16 | 坎莫森特里克斯公司 | 使用ccr9抑制剂和抗il-23阻断抗体治疗炎症性肠病的组合物和方法 |
| CN115477626B (zh) * | 2021-06-16 | 2024-08-02 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物及其用途 |
| CN118206536A (zh) * | 2022-12-15 | 2024-06-18 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物的固体形式 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0612247A1 (de) | 1991-11-15 | 1994-08-31 | Byk Gulden Lomberg Chemische Fabrik GmbH | Verwendung von sulfonylverbindungen |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| WO2001092437A1 (en) | 2000-06-01 | 2001-12-06 | Nippon Steel Chemical Co., Ltd. | Organic electroluminescent element material and organic electroluminescent element |
| CA2500492C (en) | 2002-11-18 | 2010-03-16 | Solomon Ungashe | Aryl sulfonamides |
| US20060111351A1 (en) | 2002-11-18 | 2006-05-25 | Solomon Ungashe | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US20070021466A1 (en) | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| JP4322062B2 (ja) * | 2003-07-23 | 2009-08-26 | 日本発條株式会社 | エンジンブロックおよびその製造方法 |
| KR100955170B1 (ko) | 2004-03-03 | 2010-04-29 | 키모토 컴파니 리미티드 | 광제어 필름 및 그것을 사용한 백라이트 장치 |
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| ATE503741T1 (de) | 2005-01-14 | 2011-04-15 | Chemocentryx Inc | Heteroarylsulfonamide und ccr2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| WO2007014054A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| WO2008010934A2 (en) | 2006-07-14 | 2008-01-24 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
-
2007
- 2007-07-10 US US11/775,601 patent/US7683176B2/en active Active
- 2007-07-10 ES ES07810331T patent/ES2358618T3/es active Active
- 2007-07-10 CA CA2657670A patent/CA2657670C/en active Active
- 2007-07-10 EP EP07810331A patent/EP2049515B1/en active Active
- 2007-07-10 AT AT07810331T patent/ATE496905T1/de not_active IP Right Cessation
- 2007-07-10 CN CN200780033360XA patent/CN101511800B/zh active Active
- 2007-07-10 AU AU2007272972A patent/AU2007272972B2/en active Active
- 2007-07-10 ES ES07836049T patent/ES2360741T3/es active Active
- 2007-07-10 DE DE602007012261T patent/DE602007012261D1/de active Active
- 2007-07-10 JP JP2009520761A patent/JP5320291B2/ja active Active
- 2007-07-10 WO PCT/US2007/015786 patent/WO2008008375A2/en not_active Ceased
-
2010
- 2010-02-19 US US12/708,900 patent/US8445518B2/en active Active